CSChiharu Sako

Chiharu Sako

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Chiharu Sako has a total of 610 co-authors. Here are the top co-authors by number of shared publications:

  • Christos Davatzikos

    Artificial Intelligence in Biomedical Imaging Laboratory (AIBIL), Center for AI and Data Science for Integrated Diagnostics (AI2D), Perelman School of Medicine, University of Pennsylvania, Philadelphia, USA

    15 shared publications
  • Spyridon Bakas

    Division of Computational Pathology, Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, IN, USA

    14 shared publications
  • Hamed Akbari

    Department of Bioengineering, School of Engineering, Santa Clara University, Santa Clara, CA, USA

    9 shared publications
  • Sarthak Pati

    Division of Computational Pathology, Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, IN, USA; Department of Informatics, Technical University of Munich, Munich, Germany

    9 shared publications
  • Gaurav Shukla

    Center for Biomedical Image Computing and Analytics (CBICA), University of Pennsylvania, Philadelphia, PA, USA

    8 shared publications
  • Suyash Mohan

    Department of Radiology, University of Pennsylvania, Philadelphia, USA

    8 shared publications

Latest Publications

  • Open Access

    Personalized machine learning-guided radiation dose escalation in newly diagnosed glioblastoma: prospective pilot study

    by Hamed Akbari, Suyash Mohan, Fang Liu, Cecilia Jiang, Anahita Fathi Kazerooni, Melanie Berger, Saima Rathore, Michel Bilello, Chiharu Sako, Jose Garcia, et al.

    Glioblastoma is a highly aggressive primary brain tumor with near-universal recurrence despite maximal safe resection followed by standard chemoradiation. We conducted a prospective pilot study (ClinicalTrials.gov identifier: NCT03477513) with predefined endpoints and structured dose-escalation criteria to evaluate the feasibility and safety of personalized precision radiation therapy (PPRT) guided by machine learning (ML)-based maps of tumor infiltration. Twenty patients with newly diagnosed IDH-wildtype glioblastoma who underwent gross total resection received PPRT with concomitant and adjuvant temozolomide. The primary outcomes were median progression-free survival (PFS) and safety. Secondary outcomes included patterns of recurrence, rate of clinically significant toxicity, and median overall survival (OS). PPRT was feasible and well tolerated, with no grade ≥3 acute adverse events; 47% experienced grade 1 and 53% grade 2 events. Following therapy, radiation necrosis occurred in 47% of PPRT-temozolomide patients versus 12% in standard-of-care patients (p < 0.001). Median PFS was 24.4 months versus 11.6 months in 68 propensity score matched (PSM) historical control group (HR 0.28, 95% CI 0.13-0.61; p = 0.001). Median OS was 35.4 versus 17.7 months (HR 0.34, 95% CI 0.17-0.69; p = 0.003). Exploratory post hoc comparison suggests improved survival, but these findings are preliminary and require validation in randomized trials.


  • Top Cited Papers
    Open Access

    Towards fair decentralized benchmarking of healthcare AI algorithms with the Federated Tumor Segmentation (FeTS) challenge

    by Maximilian Zenk, Ujjwal Baid, Sarthak Pati, Akis Linardos, Brandon Edwards, Micah Sheller, Patrick Foley, Alejandro Aristizabal, David Zimmerer, Alexey Gruzdev, et al.

    Computational competitions are the standard for benchmarking medical image analysis algorithms, but they typically use small curated test datasets acquired at a few centers, leaving a gap to the reality of diverse multicentric patient data. To this end, the Federated Tumor Segmentation (FeTS) Challenge represents the paradigm for real-world algorithmic performance evaluation. The FeTS challenge is a competition to benchmark (i) federated learning aggregation algorithms and (ii) state-of-the-art segmentation algorithms, across multiple international sites. Weight aggregation and client selection techniques were compared using a multicentric brain tumor dataset in realistic federated learning simulations, yielding benefits for adaptive weight aggregation, and efficiency gains through client sampling. Quantitative performance evaluation of state-of-the-art segmentation algorithms on data distributed internationally across 32 institutions yielded good generalization on average, albeit the worst-case performance revealed data-specific modes of failure. Similar multi-site setups can help validate the real-world utility of healthcare AI algorithms in the future.


  • Open Access

    The radiogenomic and spatiogenomic landscapes of glioblastoma and their relationship to oncogenic drivers

    by Anahita Fathi Kazerooni, Hamed Akbari, Xiaoju Hu, Vikas Bommineni, Dimitris Grigoriadis, Erik Toorens, Chiharu Sako, Elizabeth Mamourian, Dominique Ballinger, Robyn Sussman, et al.

    Background Glioblastoma is a highly heterogeneous brain tumor, posing challenges for precision therapies and patient stratification in clinical trials. Understanding how genetic mutations influence tumor imaging may improve patient management and treatment outcomes. This study investigates the relationship between imaging features, spatial patterns of tumor location, and genetic alterations in IDH-wildtype glioblastoma, as well as the likely sequence of mutational events. Methods We conducted a retrospective analysis of 357 IDH-wildtype glioblastomas with pre-operative multiparametric MRI and targeted genetic sequencing data. Radiogenomic signatures and spatial distribution maps were generated for key mutations in genes such as EGFR, PTEN, TP53, and NF1 and their corresponding pathways. Machine and deep learning models were used to identify imaging biomarkers and stratify tumors based on their genetic profiles and molecular heterogeneity. Results Here, we show that glioblastoma mutations produce distinctive imaging signatures, which are more pronounced in tumors with less molecular heterogeneity. These signatures provide insights into how mutations affect tumor characteristics such as neovascularization, cell density, invasion, and vascular leakage. We also found that tumor location and spatial distribution correlate with genetic profiles, revealing associations between tumor regions and specific oncogenic drivers. Additionally, imaging features reflect the cross-sectionally inferred evolutionary trajectories of glioblastomas. Conclusions This study establishes clinically accessible imaging biomarkers that capture the molecular composition and oncogenic drivers of glioblastoma. These findings have potential implications for noninvasive tumor profiling, personalized therapies, and improved patient stratification in clinical trials.


  • Open Access

    Real-World and Clinical Trial Validation of a Deep Learning Radiomic Biomarker for PD-(L)1 Immune Checkpoint Inhibitor Response in Advanced Non–Small Cell Lung Cancer

    by Chiharu Sako, Chong Duan, Kevin Maresca, Sean Kent, Taly Gilat Schmidt, Hugo J.W.L. Aerts, Ravi B. Parikh, George R. Simon, Petr Jordan

    PURPOSE: This study developed and validated a novel deep learning radiomic biomarker to estimate response to immune checkpoint inhibitor (ICI) therapy in advanced non–small cell lung cancer (NSCLC) using real-world data (RWD) and clinical trial data. MATERIALS AND METHODS: Retrospective RWD of 1,829 patients with advanced NSCLC treated with PD-(L)1 ICIs were collected from 10 academic and community institutions in the United States and Europe. The RWD included data sets for discovery (Data Set A-Discovery, n = 1,173) and independent test (Data Set B, n = 458). A radiomic pipeline, containing a deep learning feature extractor and a survival model, generated the computed tomography (CT) response score (CTRS) applied to the pretreatment routine CT/positron emission tomography (PET)-CT scan. An enhanced CTRS (eCTRS) also incorporated age, sex, treatment line, and lesion annotations. Performance was evaluated against progression-free survival (PFS) and overall survival (OS). Biomarker generalizability was further evaluated using a secondary analysis of a prospective clinical trial (ClinicalTrials.gov identifier: NCT02573259 ) evaluating the PD-1 inhibitor sasanlimab in second or later line of treatment (Data Set C, n = 54). RESULTS: In RWD Test Data Set B, the CTRS identified patients with a high probability of response to ICI with a PFS hazard ratio (HR) of 0.46 (95% CI, 0.26 to 0.82) and an OS HR of 0.50 (95% CI, 0.28 to 0.92) in the first-line ICI monotherapy cohort, after adjustment for baseline covariates including the PD-L1 tumor proportion score. In Clinical Trial Data Set C, the CTRS demonstrated an adjusted PFS HR of 1.03 (95% CI, 0.43 to 2.47) and an OS HR of 0.33 (95% CI, 0.14 to 0.91). The CTRS and eCTRS outperformed traditional imaging biomarkers of lesion size in PFS and OS for RWD Test Data Set B and in OS for the Clinical Trial Data Set. CONCLUSION: The study developed and validated a deep learning radiomic biomarker using pretreatment routine CT/PET-CT scans to identify ICI benefit in advanced NSCLC.


  • Predicting peritumoral glioblastoma infiltration and subsequent recurrence using deep-learning–based analysis of multi-parametric magnetic resonance imaging

    by Sunwoo Kwak, Hamed Akbari, Jose A. Garcia, Suyash Mohan, Yehuda Dicker, Chiharu Sako, Yuji Matsumoto, MacLean P. Nasrallah, Mahmoud Shalaby, Donald M. O’rOurke, et al.

    PurposeGlioblastoma (GBM) is the most common and aggressive primary adult brain tumor. The standard treatment approach is surgical resection to target the enhancing tumor mass, followed by adjuvant chemoradiotherapy. However, malignant cells often extend beyond the enhancing tumor boundaries and infiltrate the peritumoral edema. Traditional supervised machine learning techniques hold potential in predicting tumor infiltration extent but are hindered by the extensive resources needed to generate expertly delineated regions of interest (ROIs) for training models on tissue most and least likely to be infiltrated.ApproachWe developed a method combining expert knowledge and training-based data augmentation to automatically generate numerous training examples, enhancing the accuracy of our model for predicting tumor infiltration through predictive maps. Such maps can be used for targeted supra-total surgical resection and other therapies that might benefit from intensive yet well-targeted treatment of infiltrated tissue. We apply our method to preoperative multi-parametric magnetic resonance imaging (mpMRI) scans from a subset of 229 patients of a multi-institutional consortium (Radiomics Signatures for Precision Diagnostics) and test the model on subsequent scans with pathology-proven recurrence.ResultsLeave-one-site-out cross-validation was used to train and evaluate the tumor infiltration prediction model using initial pre-surgical scans, comparing the generated prediction maps with follow-up mpMRI scans confirming recurrence through post-resection tissue analysis. Performance was measured by voxel-wised odds ratios (ORs) across six institutions: University of Pennsylvania (OR: 9.97), Ohio State University (OR: 14.03), Case Western Reserve University (OR: 8.13), New York University (OR: 16.43), Thomas Jefferson University (OR: 8.22), and Rio Hortega (OR: 19.48).ConclusionsThe proposed model demonstrates that mpMRI analysis using deep learning can predict infiltration in the peri-tumoral brain region for GBM patients without needing to train a model using expert ROI drawings. Results for each institution demonstrate the model’s generalizability and reproducibility.


  • Open Access

    Author Correction: Federated learning enables big data for rare cancer boundary detection

    by Sarthak Pati, Ujjwal Baid, Brandon Edwards, Micah Sheller, Shih-Han Wang, G Anthony Reina, Patrick Foley, Alexey Gruzdev, Deepthi Karkada, Christos Davatzikos, et al.


  • Top Cited Papers
    Open Access

    Federated learning enables big data for rare cancer boundary detection

    by Sarthak Pati, Ujjwal Baid, Brandon Edwards, Micah Sheller, Shih-Han Wang, G. Anthony Reina, Patrick Foley, Alexey Gruzdev, Deepthi Karkada, Christos Davatzikos, et al.

    Although machine learning (ML) has shown promise across disciplines, out-of-sample generalizability is concerning. This is currently addressed by sharing multi-site data, but such centralization is challenging/infeasible to scale due to various limitations. Federated ML (FL) provides an alternative paradigm for accurate and generalizable ML, by only sharing numerical model updates. Here we present the largest FL study to-date, involving data from 71 sites across 6 continents, to generate an automatic tumor boundary detector for the rare disease of glioblastoma, reporting the largest such dataset in the literature (n = 6, 314). We demonstrate a 33% delineation improvement for the surgically targetable tumor, and 23% for the complete tumor extent, over a publicly trained model. We anticipate our study to: 1) enable more healthcare studies informed by large diverse data, ensuring meaningful results for rare diseases and underrepresented populations, 2) facilitate further analyses for glioblastoma by releasing our consensus model, and 3) demonstrate the FL effectiveness at such scale and task-complexity as a paradigm shift for multi-site collaborations, alleviating the need for data-sharing.


  • The federated tumor segmentation (FeTS) tool: an open-source solution to further solid tumor research

    by Sarthak Pati, Ujjwal Baid, Brandon Edwards, Micah J Sheller, Patrick Foley, G Anthony Reina, Siddhesh Thakur, Chiharu Sako, Michel Bilello, Christos Davatzikos, et al.

    Objective. De-centralized data analysis becomes an increasingly preferred option in the healthcare domain, as it alleviates the need for sharing primary patient data across collaborating institutions. This highlights the need for consistent harmonized data curation, pre-processing, and identification of regions of interest based on uniform criteria. Approach. Towards this end, this manuscript describes the Fe derated T umor S egmentation (FeTS) tool, in terms of software architecture and functionality. Main results. The primary aim of the FeTS tool is to facilitate this harmonized processing and the generation of gold standard reference labels for tumor sub-compartments on brain magnetic resonance imaging, and further enable federated training of a tumor sub-compartment delineation model across numerous sites distributed across the globe, without the need to share patient data. Significance. Building upon existing open-source tools such as the Insight Toolkit and Qt, the FeTS tool is designed to enable training deep learning models targeting tumor delineation in either centralized or federated settings. The target audience of the FeTS tool is primarily the computational researcher interested in developing federated learning models, and interested in joining a global federation towards this effort. The tool is open sourced at https://github.com/FETS-AI/Front-End .


  • Top Cited Papers
    Open Access

    The University of Pennsylvania glioblastoma (UPenn-GBM) cohort: advanced MRI, clinical, genomics, & radiomics

    by Spyridon Bakas, Chiharu Sako, Hamed Akbari, Michel Bilello, Aristeidis Sotiras, Gaurav Shukla, Jeffrey D. Rudie, Natali Flores Santamaría, Anahita Fathi Kazerooni, Sarthak Pati, et al.

    Glioblastoma is the most common aggressive adult brain tumor. Numerous studies have reported results from either private institutional data or publicly available datasets. However, current public datasets are limited in terms of: a) number of subjects, b) lack of consistent acquisition protocol, c) data quality, or d) accompanying clinical, demographic, and molecular information. Toward alleviating these limitations, we contribute the “University of Pennsylvania Glioblastoma Imaging, Genomics, and Radiomics” (UPenn-GBM) dataset, which describes the currently largest publicly available comprehensive collection of 630 patients diagnosed withde novoglioblastoma. The UPenn-GBM dataset includes (a) advanced multi-parametric magnetic resonance imaging scans acquired during routine clinical practice, at the University of Pennsylvania Health System, (b) accompanying clinical, demographic, and molecular information, (d) perfusion and diffusion derivative volumes, (e) computationally-derived and manually-revised expert annotations of tumor sub-regions, as well as (f) quantitative imaging (also known as radiomic) features corresponding to each of these regions. This collection describes our contribution towards repeatable, reproducible, and comparative quantitative studies leading to new predictive, prognostic, and diagnostic assessments.


  • Optimization of Deep Learning Based Brain Extraction in MRI for Low Resource Environments

    by Siddhesh P. Thakur, Sarthak Pati, Ravi Panchumarthy, Deepthi Karkada, Junwen Wu, Dmitry Kurtaev, Chiharu Sako, Prashant Shah, Spyridon Bakas

    Brain extraction is an indispensable step in neuro-imaging with a direct impact on downstream analyses. Most such methods have been developed for non-pathologically affected brains, and hence tend to suffer in performance when applied on brains with pathologies, e.g., gliomas, multiple sclerosis, traumatic brain injuries. Deep Learning (DL) methodologies for healthcare have shown promising results, but their clinical translation has been limited, primarily due to these methods suffering from i) high computational cost, and ii) specific hardware requirements, e.g., DL acceleration cards. In this study, we explore the potential of mathematical optimizations, towards making DL methods amenable to application in low resource environments. We focus on both the qualitative and quantitative evaluation of such optimizations on an existing DL brain extraction method, designed for pathologically-affected brains and agnostic to the input modality. We conduct direct optimizations and quantization of the trained model (i.e., prior to inference on new data). Our results yield substantial gains, in terms of speedup, latency, throughput, and reduction in memory usage, while the segmentation performance of the initial and the optimized models remains stable, i.e., as quantified by both the Dice Similarity Coefficient and the Hausdorff Distance. These findings support post-training optimizations as a promising approach for enabling the execution of advanced DL methodologies on plain commercial-grade CPUs, and hence contributing to their translation in limited- and low- resource clinical environments. Keywords Low resource environment Deep learning Segmentation CNN Convolutional neural network Brain extraction Brain tumor Glioma Glioblastoma BraTS OpenVINO BrainMaGe GaNDLF